company background image
ADMA logo

ADMA Biologics NasdaqGM:ADMA Stock Report

Last Price

US$5.94

Market Cap

US$1.4b

7D

-3.9%

1Y

92.9%

Updated

18 Mar, 2024

Data

Company Financials +

ADMA Biologics, Inc.

NasdaqGM:ADMA Stock Report

Market Cap: US$1.4b

ADMA Stock Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

ADMA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ADMA Biologics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ADMA Biologics
Historical stock prices
Current Share PriceUS$5.94
52 Week HighUS$6.42
52 Week LowUS$2.95
Beta0.43
1 Month Change12.50%
3 Month Change40.76%
1 Year Change92.86%
3 Year Change185.58%
5 Year Change80.00%
Change since IPO-30.36%

Recent News & Updates

ADMA Biologics: On A Roll Entering 2024

Jan 19

Recent updates

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Dec 02
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: Turning A Corner

Nov 20

ADMA: Insiders Showing Their Cards

Nov 02

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

Aug 22

ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

Aug 14

Shareholders May Be A Bit More Conservative With ADMA Biologics, Inc.'s (NASDAQ:ADMA) CEO Compensation For Now

May 22
Shareholders May Be A Bit More Conservative With ADMA Biologics, Inc.'s (NASDAQ:ADMA) CEO Compensation For Now

ADMA Bio shares surge 23% on FDA approval for increased IVIG production scale

Apr 28

Shareholder Returns

ADMAUS BiotechsUS Market
7D-3.9%-2.1%-0.1%
1Y92.9%10.4%28.4%

Return vs Industry: ADMA exceeded the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: ADMA exceeded the US Market which returned 28.4% over the past year.

Price Volatility

Is ADMA's price volatile compared to industry and market?
ADMA volatility
ADMA Average Weekly Movement6.0%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ADMA's share price has been volatile over the past 3 months.

Volatility Over Time: ADMA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004624Adam Grossmanhttps://www.admabiologics.com

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.

ADMA Biologics, Inc. Fundamentals Summary

How do ADMA Biologics's earnings and revenue compare to its market cap?
ADMA fundamental statistics
Market capUS$1.36b
Earnings (TTM)-US$28.24m
Revenue (TTM)US$258.22m

5.2x

P/S Ratio

-48.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADMA income statement (TTM)
RevenueUS$258.22m
Cost of RevenueUS$167.17m
Gross ProfitUS$91.04m
Other ExpensesUS$119.28m
Earnings-US$28.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.12
Gross Margin35.26%
Net Profit Margin-10.94%
Debt/Equity Ratio96.6%

How did ADMA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.